TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00799149

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin, Etoricoxib, Sugar pill
Description: Control (Sugar pill) or gabapentin (1200 mg) or etoricoxib (120 mg) administered 30-90 min before the patient entered the operating room with a sip of water. Subsequent doses of the oral study drugs were administered on the mornings (08H00) of the first, second, and third postoperative days. .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin, Etoricoxib, Sugar pill
Description: Control (Sugar pill) or gabapentin (1200 mg) or etoricoxib (120 mg) administered 30-90 min before the patient entered the operating room with a sip of water. Subsequent doses of the oral study drugs were administered on the mornings (08H00) of the first, second, and third postoperative days. .

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gabapentin, Etoricoxib, Sugar pill
Description: Control (Sugar pill) or gabapentin (1200 mg) or etoricoxib (120 mg) administered 30-90 min before the patient entered the operating room with a sip of water. Subsequent doses of the oral study drugs were administered on the mornings (08H00) of the first, second, and third postoperative days. .
Study: NCT01357993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNS001
Description: 18 mg, 27 mg and 36 mg tablets (18-72 mg/day) once daily for 48 weeks
Study: NCT01934634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCL161
Description: LCL161 (tablets): 300, 600, 1200, or 1800 mg once a week (Day 1, 8, 15) for 3 weeks, every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine IV: 1,000 mg/m2 once a week (Day 1, 8, 15) for 3 weeks, every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel
Description: nab-paclitaxel IV: 125 mg/m2 once a week (Day 1, 8, 15) for 3 weeks, every 28 days
Study: NCT01848990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Commercial Hylenex® recombinant (hyaluronidase human injection)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Precommercial Hylenex recombinant (hyaluronidase human injection)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin lispro

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin lispro

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin lispro

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin aspart

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin aspart
Study: NCT04337502

Intervention type: DIAGNOSTIC_TEST
Intervention: Machine learning model
Description: Machine learning, such as logistic regression, random forest, and deep learning
Study: NCT01848990

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin aspart

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glulisine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glulisine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glulisine
Study: NCT01876264

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extended resection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional resection
Study: NCT01437228

Intervention type: DRUG
Group type: OTHER
Intervention: povidone- iodine solution.
Description: %10 Polivinilpirolidon iyot (Polividon- iyot

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: NO İNTERVENTİON
Study: NCT02044536

Intervention type: OTHER
Intervention: No intervention
Description: retrospective data review

Intervention type: OTHER
Intervention: No intervention
Description: retrospective data review
Study: NCT00360776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tipifarnib
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01122511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 700 ug dexamethasone
Description: Intravitreal injection of 700 ug dexamethasone into study eye
Study: NCT01122511

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ranibizumab
Description: Intravitreal injection of ranibizumab into study eye

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab
Description: Intravitreal injection of ranibizumab into study eye

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sham
Description: Sham needle-less injection administered in the study eye
Study: NCT03724695

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinician nudge or opt out approach for AHCAH liaison visit
Description: This study is a nudge or opt-out approach of an AHCAH liaison visit to eligible seriously ill HF patients prior to hospital discharge to discuss the AHCAH program and to subsequently facilitate enrolling them in the AHCAH program if they are amenable, compared to the opt-in approach (usual care).
Study: NCT03427177

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mychoice
Description: The mychoice communication tool begins to prepare patients to participate in a personal and tailored discussion with their provider about clinical trials as a potential treatment option. It is also customized to address the concerns of those least likely to participate, instead of providing a more general look at clinical trials- a common trait of other available tools.
Study: NCT03574623

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical Stimulator
Description: An electrical stimulator will be used to deliver electrical current through surface electrodes to produce hand opening by making the paretic finger and thumb extensor muscles contract. The stimulator can be programmed to turn on and off in a repetitive cyclic fashion (i.e., cNMES) or be programmed to deliver stimulation with an intensity that corresponds to the opening of a glove instrumented with sensors and plugged into the stimulator (i.e., CCFES).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electrical Stimulator
Description: An electrical stimulator will be used to deliver electrical current through surface electrodes to produce hand opening by making the paretic finger and thumb extensor muscles contract. The stimulator can be programmed to turn on and off in a repetitive cyclic fashion (i.e., cNMES) or be programmed to deliver stimulation with an intensity that corresponds to the opening of a glove instrumented with sensors and plugged into the stimulator (i.e., CCFES).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Occupational Therapy
Description: Task practice that requires movement and use of the paretic hand under the guidance of a trained therapist.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Occupational Therapy
Description: Task practice that requires movement and use of the paretic hand under the guidance of a trained therapist.
Study: NCT06585319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Collagen-polyvinylpyrrolidone
Description: 2 ml intramuscular q24 h

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pirfenidone 1200 mg
Description: 1,200 mg of oral q12 h
Study: NCT03356145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 12 mL paracervical block
Description: Injection of 12 mL of lidocaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 20 mL paracervical block
Description: Injection of 20 mL of lidocaine
Study: NCT03574623

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Occupational Therapy
Description: Task practice that requires movement and use of the paretic hand under the guidance of a trained therapist.
Study: NCT03415412

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clearfil Univesal Bond
Description: Adhesive systems

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IBond Universal
Description: Adhesive systems
Study: NCT04066452

Intervention type: DIAGNOSTIC_TEST
Intervention: Proteinogram and serum immunoglobulins. Light chains free in serum -Freelite-. Immunofixation in serum and urine
Description: Analysis to rule out the presence of monoclonal protein in blood and urine.
Study: NCT01522911

Intervention type: DEVICE
Group type: OTHER
Intervention: WATCHMAN LAA system (Percutaneous left atrial appendage closure)
Description: The WATCHMAN LAA system (Altritech Inc., Plymouth, MN),Percutaneous occlusion systems have been developed as an alternative to anticoagulation for stroke prevention. Briefly, transseptal puncture is performed to gain access to the left atrial appendage (LAA). Thereafter LAA angiography is performed. After an optimal device size is chosen based on LAA measurements by fluoro and echocardiography the occluder is implanted into the orifice of the left atrial appendage under fluoroscopy and TEE-guidance. The size of the device is chosen to be 10% to 20% larger than diameter of the LAA ostium to have stable positioning of the device. Every procedure is performed under local anaesthesia. Heparin is given during implantation procedure to achieve an activated clotting time of at least 250.
Study: NCT04418557

Intervention type: DIAGNOSTIC_TEST
Intervention: RT-PCR and antibody testing
Description: Testing of amniotic fluid, cord blood, amnion and chorion, umbilical cord, vaginal mucous, maternal and neonatal sera, neonatal throat swab, and breast milk.

Intervention type: DIAGNOSTIC_TEST
Intervention: RT-PCR and antibody testing
Description: Testing of amniotic fluid, cord blood, amnion and chorion, umbilical cord, vaginal mucous, maternal and neonatal sera, neonatal throat swab, and breast milk.
Study: NCT01060267

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erythromycin
Description: The patients in erythromycin group received intravenous bolus infusion of 125 mg of erythromycin lactobionate in 50 ml of normal saline

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Placebo
Description: patients in placebo group 50ml of normal saline over 10 minutes, 1/2 hour before endoscopy.
Study: NCT01712984

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Vaccine USP Quadrivalent, (Zonal Purified Subvirion) 2012 2013 Formulation
Description: 0.1mL, Intradermal

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza Virus Vaccine USP Trivalent Types A and B (Zonal Purified Subvirion) Fluzone® Intradermal
Description: 0.1mL, Intradermal

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza Virus Vaccine USP Trivalent Types A and B (Zonal Purified Subvirion) Fluzone Intradermal
Description: 0.1mL, Intradermal
Study: NCT01595724

Intervention type: DRUG
Intervention: Visanne (Dienogest, BAY86-5258)
Description: Intake of Dienogest 2mg/day to treat Endometriosis according to regular clinical practice.
Study: NCT04284657

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pravastatin
Description: Pravastatin 40 mg QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pravastatin
Description: Pravastatin 40 mg QD
Study: NCT03415412

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: G-Premio Bond
Description: Adhesive systems
Study: NCT04284657

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium citrate
Description: sodium citrate up to 30 ml TID
Study: NCT01687166

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blazer Open-Irrigated Ablation Catheter (Boston Scientific)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FDA Approved Open-Irrigated Ablation Catheter
Study: NCT02966171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMPL-453
Description: oral administration
Study: NCT04102514

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Real-time Group Video
Description: Dyads in the RGV arm will be asked to complete three 45 min sessions that include aerobic, resistance, and balance/coordination exercises delivered by a trained health coach via Zoom® software on an iPad during mos. 0-6, and 1 session/wk. during mos. 7-12 to groups of 5-8 dyads in their home along with being provided written materials regarding exercise and physical activity from the National Institute on Aging and brief (15-20 min) FaceTime meetings (0-6 mos.= 2/mo.; 7-12 mos.= 1/mo.) with the heath coach to discuss progress, provide support and receive additional guidance on how to increase MPA.
Study: NCT00809562

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: po daily for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4917523
Description: orally daily for 10 days, cohorts receiving up to 5 different doses (according to safety and tolerability)
Study: NCT02543931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meriva
Description: Meriva is an enhanced-bioavailability, curcuminoid-enriched turmeric dietary supplement that is sold over the counter in the United States and other countries.
Study: NCT03554200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: Standard of Care + Empagliflozin: 10 mg (tablets) once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Standard of Care + Placebo: Matching Placebo (tablets) once daily
Study: NCT04102514

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Enhanced Usual Care
Description: Dyads in the EUC arm, will be given a recommended exercise plan to follow on their own along with being provided written materials regarding exercise and physical activity from the National Institute on Aging and brief (15-20 min) FaceTime meetings (0-6 mos.= 2/mo.; 7-12 mos.= 1/mo.) with the heath coach to discuss progress, provide support and receive additional guidance on how to increase MPA.
Study: NCT05134545

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Genoss® DCB
Description: Peripheral Drug Coated Balloon
Study: NCT02543931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meriva
Description: Meriva is an enhanced-bioavailability, curcuminoid-enriched turmeric dietary supplement that is sold over the counter in the United States and other countries.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo capsules containing inert ingredients
Study: NCT04666090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carillizumab
Description: administration regimen: Carillizumab 200mg, IV, D1; Albumin paclitaxel 150mg/m2, D1; Nedaplatin 50 mg/m2, D1; Apatinib 250mg Po D2-4. Preoperative neoadjuvant therapy for 2-3 cycles, one cycle every 14 days.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Esophagectomy
Description: Laparoscopy combined with thoracoscope radical resection of esophageal carcinoma

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Samples
Description: Blood, Tumour and Saliva will be Collected from participant. Fate of sample is Destruction after use
Study: NCT04122443

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Acetaminophen 650mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Acetaminophen 650mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: Oxycodone 10mg
Study: NCT02916745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Porfimer sodium
Description: After injection of porfimer sodium (Photofrin®), a flexible bronchoscopy with navigation guidance will be performed to confirm the location and the size of the lesion with the use of radial probe endobronchial ultrasonography (REBUS). A light dose of 200 J/cm of diffuser length will be delivered.
Study: NCT00462956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tykerb
Description: lapatinib 1500mg daily
Study: NCT03427385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5%
Description: The volume of local anesthetic Ropivacaine 0.5% will be determined by the response (success or failure of block, 30 minutes after local anesthetic injection) of the previous patient in that group. Block success is defined as an absence of ice sensation in the knee within 30 min of ropivacaine administration accompanied by tolerance to tetanic electrical stimulation (TES) at 60 mA(milliamp) for 5 seconds.
Study: NCT01659424

Intervention type: RADIATION
Group type: OTHER
Intervention: High Dose Rate Endorectal Brachytherapy (HDR-ERBT)
Description: Combining pre-operative FOLFOX chemotherapy with HDR-ERBT (Radiation therapy) followed by surgery then additional FOLFOX chemotherapy to decrease the risk of distant metastasis and to maintain excellent locoregional control with decreased morbidity.
Study: NCT00183872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan, docetaxel
Description: docetaxel 30 mg/m2 IV infusion days 1 and 8, with irinotecan 65 mg/m2 IV infusion on days 1 and 8.
Study: NCT01257594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: For patients with no cytoreductive surgery planned, patients will receive single-agent erlotinib at a starting dose of 2000 mg on days 1 of every 7 days. For patients with cytoreductive surgery planned, patients will receive single-agent erlotinib at a starting dose of 2000 mg day 1 of every 7 days (+/- 2 days). One pre-operative dose of 2000 mg erlotinib will be administered in an open-label, unblinded manner, administered in the hospital on call to the operating room.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: For patients with no cytoreductive surgery planned, patients will receive single-agent erlotinib at a starting dose of 2000 mg on days 1 of every 7 days. For patients with cytoreductive surgery planned, patients will receive single-agent erlotinib at a starting dose of 2000 mg day 1 of every 7 days (+/- 2 days). One pre-operative dose of 2000 mg erlotinib will be administered in an open-label, unblinded manner, administered in the hospital on call to the operating room.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cytoreductive Surgery
Description: Standard procedure
Study: NCT01640730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kanglaite Injection
Description: 30gm IV infusion 5 days a week for 3 weeks every 28 days
Study: NCT03097419

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote post-ischemic conditioning
Description: A manual sphygmomanometer will be inflated over the brachial artery of the participants' arm that does not have an intravenous catheter actively infusing medications. If both arms are in use, then the participant's non-dominant arm will be used.~* The sphygmomanometer will be inflated to a pressure at least 20 mmHg greater than the participants' last recorded systolic blood pressure.~* The sphygmomanometer will be inflated for 5 minutes then rapidly deflated for 5 minutes, thereby concluding one iteration.~* Five (5) total iterations constitute the treatment.~* The left arm will be preferentially used instead of the right arm, unless the left arm is receiving medication administration.
Study: NCT02036099

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Driving in Mild Dementia Decision Tool
Study: NCT02962037

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Melatonin and light therapy
Study: NCT01977417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salsalate
Study: NCT02088658

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technology Intensified
Description: The intervention is based on the Information-Motivation-Behavioral Skills (IMB) model and provides information, motivation, and behavioral skills training (using motivational enhancement techniques). Patients will be assigned the FORA 2-in-1 Telehealth System and provided glucose test strips to allow testing at least once a day. They will be asked to perform glucose testing and blood pressure measurement using the FORA system once daily. They will be asked to upload the measurements daily as soon as possible after the test is performed. The nurse educators will have access to a secure server to which the uploaded measurements are stored in real time. The glucose and BP readings will be used to tailor and reinforce behavior change during weekly telephone-delivered diabetes education sessions.
Study: NCT02469610

Intervention type: OTHER
Group type: OTHER
Intervention: Intercostal block Bupivacaine based
Description: Intercostal Bupivacaine block of 100ml over five intercostal spaces.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intercostal block Bupivacaine based
Description: Intercostal Bupivacaine block of 100ml over five intercostal spaces.
Study: NCT05588596

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma Resiliency Mindfulness-Informed Intervention
Description: The total duration of the intervention was once a week for eight weeks. The aim of the intervention was to teach patients a range of trauma recovery mindfulness skills
Study: NCT03818022

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoneurolysis (Iovera)
Description: Cryoneurolysis performed by radiology department 1 week prior to total knee arthroplasty
Study: NCT05134545

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IN.PACT Admiral® DCB
Description: Peripheral Drug Coated Balloon
Study: NCT00797953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T89
Description: A two-herb botanical drug product in 62.5mg capsule formulation. It is to be used as 125mg or 187.5mg twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T89
Description: A two-herb botanical drug product in 62.5mg capsule formulation. It is to be used as 125mg or 187.5mg twice daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: T89
Description: A two-herb botanical drug product in 62.5mg capsule formulation. It is to be used as 125mg or 187.5mg twice daily.
Study: NCT02397356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine first AB
Description: Nebulised ketamine 1mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine first AB
Description: Nebulised ketamine 1mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo first BA
Description: Nebulised saline 1-2ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo first BA
Description: Nebulised saline 1-2ml
Study: NCT01977417

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02916745

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fiber optic
Description: A fiber optic diffuser length matching the tumor length will be placed in the lesion under fluoroscopy guidance.
Study: NCT01723228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rasagiline
Study: NCT04214834

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Rapid-wean: 176 treated Slow-wean: 75 treated
Study: NCT04242498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Description: Subjects will receive bimekizumab at pre-specified time-points.
Study: NCT01723228

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00656253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herbal Medicinal Mixture (Roucongrong, Heshouwu etc.)
Description: 12 months period of Herbal Medicinal Mixture per day plus 1 month wash-out period without herbal medicine